Literature DB >> 22237767

Plasma vitamin C concentrations in patients on routine hemodialysis and its relationship to patients' morbidity and mortality.

Simin Dashti-Khavidaki1, Azita Hajhossein Talasaz, Hamed Tabeefar, Mannan Hajimahmoodi, Ghazaleh Moghaddam, Hossein Khalili, Mahboob Lessan-Pezeshki, Afsaneh Jahanmardi.   

Abstract

BACKGROUND: Some studies have hypothesized the protective role of vitamin C against cardiovascular disorders (CVD) in patients with end-stage renal disease (ESRD). This study was designed to assess plasma vitamin C concentration and its relationship to hemodialysis (HD) patients' morbidity and mortality.
METHODS: Plasma vitamin C concentrations were assessed in HD patients using spectrophotometry and subjects were prospectively followed for up eighteen months for all-cause mortality. Any association between vitamin C concentration and patients' demographic data, co-morbidities, or the cause of ESRD were investigated using the Chi-square test.
RESULTS: Ninety-one patients with a mean age of 56.7 ± 15.7 years were included in this study. The most frequent cause of ESRD was simultaneous hypertension and diabetes in 30 % of patients, followed by hypertension in 25.6 %, and diabetes in 11.1 %, respectively. About 34 % of patients had CVD as the most prevalent co-morbidity. Forty-nine patients (53.8 %) had low levels of vitamin C concentration. There was a significant relationship between vitamin C insufficiency and presence of any co-morbidity in HD patients (p < 0.05). There was a significant difference in vitamin C concentrations between patients without co-morbidities and those with cardiovascular ones (F[2,88]=3.447, p = 0.036). Twenty-two (24.2 %) patients died over a median duration of 227 days. There was a significant difference in time to death of patients with and without low levels of vitamin C concentration (p = 0.04).
CONCLUSIONS: The results showed lower plasma vitamin C levels in HD patients who suffered any co-morbidity and sooner time to death in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22237767     DOI: 10.1024/0300-9831/a000065

Source DB:  PubMed          Journal:  Int J Vitam Nutr Res        ISSN: 0300-9831            Impact factor:   1.784


  5 in total

1.  Vitamin C decreases reduced glutathione in chronic haemodialysis patients: a pilot, randomised, double-blind trial.

Authors:  Mayara Lopes Martins; Angela Teodósio da Silva; Roberta Pieri Machado; Hanna Pillmann Ramos; Caroline Martinelli; Taís Thomsen Silveira; Edson Luiz da Silva; Elisabeth Wazlawik
Journal:  Int Urol Nephrol       Date:  2021-04-27       Impact factor: 2.370

2.  Effects of nutritional supplementation on fatigue, and autonomic and immune dysfunction in patients with end-stage renal disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Sanae Fukuda; Hidenori Koyama; Kazuhiro Kondo; Hisako Fujii; Yoshinobu Hirayama; Tsutomu Tabata; Mikio Okamura; Tomoyuki Yamakawa; Shigeki Okada; Sumio Hirata; Hiroshi Kiyama; Osami Kajimoto; Yasuyoshi Watanabe; Masaaki Inaba; Yoshiki Nishizawa
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

3.  The effect of increased frequency of hemodialysis on vitamin C concentrations: an ancillary study of the randomized Frequent Hemodialysis Network (FHN) daily trial.

Authors:  Jochen G Raimann; Samer R Abbas; Li Liu; Brett Larive; Gerald Beck; Peter Kotanko; Nathan W Levin; Garry Handelman
Journal:  BMC Nephrol       Date:  2019-05-17       Impact factor: 2.388

Review 4.  Two Faces of Vitamin C in Hemodialysis Patients: Relation to Oxidative Stress and Inflammation.

Authors:  Patrick Chaghouri; Nour Maalouf; Sophia Lorina Peters; Piotr Jan Nowak; Katarzyna Peczek; Anna Zasowska-Nowak; Michal Nowicki
Journal:  Nutrients       Date:  2021-02-27       Impact factor: 5.717

5.  Vitamins (A, C and E) and oxidative status of hemodialysis patients treated with HFR and HFR-Supra.

Authors:  Simonetta Palleschi; Paolo M Ghezzi; Giuseppe Palladino; Barbara Rossi; Marino Ganadu; Domenica Casu; Maria Cossu; Giovanni Mattana; Antonio Maria Pinna; Bruno Contu; Tonina Ghisu; Alessandro Monni; Luana Gazzanelli; Maria Cristina Mereu; Franco Logias; Mario Passaghe; Alessandro Amore; Piergiorgio Bolasco
Journal:  BMC Nephrol       Date:  2016-08-26       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.